Zacks Investment Research downgraded Evoke Pharma Inc (NASDAQ:EVOK) to Sell in a statement released earlier today.
- Updated: March 20, 2017
Zacks Investment Research has downgraded Evoke Pharma Inc (NASDAQ:EVOK) to Sell in a statement released on 03/20/2017.
On 3/16/2017, Rodman & Renshaw released a statement for Evoke Pharma Inc (NASDAQ:EVOK) bumped up the target price from $6.00 to $9.00 that indicated a possible upside of 1.85%.
Just yesterday Evoke Pharma Inc (NASDAQ:EVOK) traded -1.63% lower at $3.01. Evoke Pharma Inc’s 50-day moving average is $3.01 and its 200-day moving average is $2.22. With the last close up 35.89% relative to the two hundred day average, compared to the S&P 500 which has increased 0.04% over the same time. 204,050 shares of Evoke Pharma Inc exchanged hands, down from an avg. volume of 1,197,170
See Chart Below
Evoke Pharma Inc has a 52 week low of $1.35 and a 52 week high of $11.11 The company’s market cap is currently $0.
In addition to Zacks Investment Research reporting its stock price target, a total of 7 brokers have issued a research note on the stock. The consensus target price is $17.68 with 2 firms rating the stock a strong buy, 4 firms rating the stock a buy, 0 firms rating the stock a hold, 0 firms rating the stock a underperform, and finally 0 firms rating the stock a sell.
About Evoke Pharma Inc (NASDAQ:EVOK)
Evoke Pharma, Inc. is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women. EVK-001 is a formulation of Metoclopramide drug, designed to provide systemic delivery of metoclopramide through intranasal administration. The Company has evaluated EVK-001 in a multicenter, randomized, double-blind, placebo-controlled parallel group, dose-ranging Phase IIb clinical trial. The Company has commenced a Phase III clinical trial of EVK-001 in female patients with symptoms associated with acute and recurrent diabetic gastroparesis. The Phase III clinical trial is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study evaluating the efficacy, safety and population pharmacokinetics of EVK-001 in adult females.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.